Treatments for Tardive Dyskinesia

An Overview of Noncatecholaminergic/Noncholinergic Treatments
  • Larry D. Alphs
  • John M. Davis


Since the late 1960s, tardive dyskinesia (TD) has been recognized as a potential sequela of prolonged therapy with neuroleptics. Besides the disfiguring movements that characterize this syndrome, TD is frequently complicated by ternperomandibular joint dysfunction, mouth ulcers, accidental trauma secondary to position instability, respiratory problems, and speech pathology. The movements themselves are often a source of social embarrassment and tend to further isolate individuals with concomitant disabling illnesses like schizophrenia. Because of its medical, social, and legal implications, TD is one of the most significant complications of pharmacological treatment for psychiatric illnesses. As a result, considerable effort has been devoted to finding a treatment for its various symptoms; however, no universally successful therapy has yet been demonstrated.


Tardive Dyskinesia Sodium Valproate Gaba Agonist Dyskinetic Movement GABAergic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alphs, L. D., and Davis, J. M., 1983, Cholinergic treatments for tardive dyskinesia, in: Modern Problems of Pharmacopsychiatry ( J. Bannet and R. H. Belmaker, eds.), Vol. 21, pp. 168–186, S. Karger AG, Basel.Google Scholar
  2. Ames, D., and Webber, J., 1984, Sodium valproate and tardive dyskinesia, Med. J. Aust. 140: 350.PubMedGoogle Scholar
  3. Amsterdam, J., and Mendels, J., 1979, Treatment resistant tardive dyskinesia, a new therapeutic approach, Am. J. Psychiatry 136: 1197–1198.PubMedGoogle Scholar
  4. Anden, N. E., and Wachtel, H., 1977, Biochemical effects of baclofen: (Beta-paraclorophenylGABA) on the dopamine and the noradrenaline in the rat brain, Acta. Pharmacol. Toxicol. 40: 310–320.Google Scholar
  5. Ashcroft, G. W., 1972, Modified amine hypothesis for the etiology of affective illness, Lancet 1: 573–577.Google Scholar
  6. Asnis, G. M., and Leopold, M. A., 1978, A single-blind study of ECT in patients with tardive dyskinesia, Am. J. Psychiatry 135: 1235–1237.PubMedGoogle Scholar
  7. Bedard, P., Langelier, P., and Villeneuve, A., 1977, Oestrogen and extrapyramidal system, Lancet 2: 1367–1368.PubMedGoogle Scholar
  8. Beitman, B. D., 1978, Tardive dyskinesia reinduced by lithium carbonate, Am. J. Psychiatry 135: 1229–1230.PubMedGoogle Scholar
  9. Bjorndal, N., Casey, D. E., and Gerlach, J., 1980, Enkephalin, morphine and naloxone in tardive dyskinesia, Psychopharmacology 69: 133–136.PubMedGoogle Scholar
  10. Bobruff, A., Gardos, G., Tarsy, D., Rapkin, R. M., Cole, J. O., and Moore, P., 1981, Clonazepam and phenobarbital in tardive dyskinesia, Am. J. Psychiatry 138: 189–193.PubMedGoogle Scholar
  11. Callen, K. E., Malek-Ahmadi, P., Davis, D., Davis, L. G., and Sorkin, M. I., 1982, The effect of hemodialysis on tardive dyskinesia, Psychosomatics 23: 869–870.PubMedGoogle Scholar
  12. Carlsson, A., 1970, Biochemical implications of dopa-induced actions on the central nervous system, with particular relevance to abnormal movements, in: L-Dopa and Parkinsonism ( A. Barbeau, and F. H. McDowell, eds.), pp. 205–213, Davis, Philadelphia.Google Scholar
  13. Casey, D. E., and Hammerstad, J. P., 1979, Sodium valproate in tardive dyskinesia, J. Clin. Psychiatry 40: 483–485.PubMedGoogle Scholar
  14. Casey, D. E., Gerlach, J., Magelund, G., and Christensen, T. R., 1980a, Gamma-acetylenic GABA in tardive dyskinesia, Arch. Gen. Psychiatry 37: 1376–1379.PubMedGoogle Scholar
  15. Casey, D. E., Gerlach, J., Magelund, G., and Christensen, T. R., 1980b, Gamma-acetylenic GABA in tardive dyskinesia, Adv. Biochem. Psychopharmacol. 24: 577–580.PubMedGoogle Scholar
  16. Casey, D. E., Korsgaard, S., Gerlach, J., Jorgensen, A., and Simmelsgaard, H., 1981, Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia, Arch. Gen. Psychiatry 38: 158–160.PubMedGoogle Scholar
  17. Chien, C., Jung, K., and Ross-Townsend, A., 1978, Efficacies of agents related to GABA, dopamine and acetylcholine in the treatment of tardive dyskinesia, Psychopharmacol Bull. 14: 20–22.PubMedGoogle Scholar
  18. Colburn, R. W., Goodwin, E. R., Bunney, W. E., and David, J. M., 1967, Effect of lithium on the uptake of noradrenaline by synaptosomes, Nature 215: 1394–1397.Google Scholar
  19. Cole, J. O., Gardos, G., Tarsy, D., Granacher, R. P., Sniffin, C., Vanderkolk, B., and Trenholm, I., 1980, Drug trials in persistent dyskinesia, in: Tardive Dyskinesia—Clinical and Basic Research ( R. Smith, W. Frann, J. Davis, and E. Domino, eds.), pp. 419–428, Spectrum Books, New York.Google Scholar
  20. Crane, G. E., Turek, I. S., and Kurland, A. A., 1970, Failure of pyridoxine to reduce drug-induced dyskinesia, J. Neurol. Neurosurg. Psychiatry 33: 511–512.PubMedGoogle Scholar
  21. Crews, E. L., and Carpenter, A. E., 1977, Lithium-induced aggravation of tardive dyskinesia, Am. J. Psychiatry 134: 933.PubMedGoogle Scholar
  22. Crowe, B. M., 1983, Symptom control in tardive dyskinesia, Br. J. Psychiatry 143: 419–420.PubMedGoogle Scholar
  23. Curtis, D. R., 1978, GABAergic transmission in the mammalian central nervous system, in: GABA-Neurotransmitters ( P. Krogsgaard-Larsen, J. Scheel-Kruger and H. Kofod, eds.), pp. 17–27, Academic Press, New York.Google Scholar
  24. Cutler, N. R., 1981, Clonazepam and tardive dyskinesa, Am. J. Psychiatry 138: 1127–1128.Google Scholar
  25. Dalen, P., 1973, Lithium therapy in Huntington’s chorea and tardive dyskinesia, Lancet 1: 107–108.PubMedGoogle Scholar
  26. DeVeaugh-Geiss, J., 1978, Aggravation of tardive dyskinesia by phenytoin, N. Engl. J. Med. 298: 457–458.PubMedGoogle Scholar
  27. DeVeaugh-Geiss, J., and Manion, L., 1978, High dose pyridoxine in tardive dyskinesia, J. Clin. Psychiatry 39: 573–575.PubMedGoogle Scholar
  28. de Wied, D., Kovacs, G. L., Bohus, B., van Ree, J. M., and Greven, H. M., 1978, Neuroleptic activity of the neuropeptide beta-LPH62–77 ((Des-tyr’)-gamma-endorphin; DyTE), Eur.J. Pharmacol. 49: 427–438.PubMedGoogle Scholar
  29. Diamond, B. I., and Borison, R. L., 1979, Enkephalins and nigro-striatal function, Neurology 28: 1085–1088.Google Scholar
  30. Druckman, R., Seelinger, D., and Thulin, B., 1962, Chronic involuntary movements induced by phenothiazines, J. Nerv. Ment. Dis. 135: 69–75.PubMedGoogle Scholar
  31. Dynes, J. B., 1970, Oral dyskinesia—Occurrence and treatment, Dis. Nerv. Syst. 31: 854–859.PubMedGoogle Scholar
  32. Ehrensing, R. H., 1974, Lithium and M. R. I. H. in tardive dyskinesia, Lancet 2: 1459–1460.PubMedGoogle Scholar
  33. Ehrensing, R. H., Kastin, A. J., Larsons, P. F., and Bishop, G. A., 1977, Melanocyte-stimulatinghormone release-inhibiting factor-I and tardive dyskinesia, Dis. Nerv. Syst. 38: 303–306.PubMedGoogle Scholar
  34. Feder, R., and Moore, D. C., 1980, Baclofen and tardive dyskinesia, Am. J. Psychiatry 137: 633–634.PubMedGoogle Scholar
  35. Ferkany, J., Butler, I., and Enna, S., 1979, Effects of drugs on rat brain cerebrospinal fluid and blood GABA content, J. Neurochem. 33: 29–33.PubMedGoogle Scholar
  36. Friis, T., Rosted Christensen, T., and Gerlach, J., 1983, Sodium valproate and biperiden in neuroleptic-induced akathesia, parkinsonism, and hyperkinesia, Acta Psychiat. Scand. 67: 178–187.PubMedGoogle Scholar
  37. Fuze, K., Hokfelt, T., Ljungdahl, A., Agnati, L., Johansson, O., and de la Mora, M., 1975, Evidence for an inhibitory GABAergic control of the mesolimbic dopamine neurons: Possibility of improving treatment of schizophrenia by combined treatment with neuroleptics and GABAergic drugs, Med. Biol. 53: 177–183.Google Scholar
  38. Gardos, G., and Cole, J. O., 1978, Pilot study of cyproheptadine (Periactin) in tardive dyskinesia, Psychopharmacol. Bull. 14: 18–20.PubMedGoogle Scholar
  39. Gerlach, J., 1977, The relationship between parkinsonism and tardive dyskinesia, Am. J. Psychiatry 134: 781.PubMedGoogle Scholar
  40. Gerlach, J., Reisby, N., and Randrup, A., 1974, Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia, Psychopharmacologia 34: 21–35.PubMedGoogle Scholar
  41. Gerlach, J., Thorsen, K., and Munkvad, I., 1975, Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind crossover trial, Pharmakopsychiatr. Neuropsychopharmakol. 8: 51–56.PubMedGoogle Scholar
  42. Gerlach, J., Rye, T., and Kristjansen, P., 1978, Effect of baclofen on tardive dyskinesia, Psycho-pharmacology 56: 145–151.Google Scholar
  43. Gibson, A. C., 1978, Sodium valproate and tardive dyskinesia, Br. J. Psychiatry 133: 82.PubMedGoogle Scholar
  44. Glazer, W. M., Naftolin, F., Moore, D. C., Bowers, M. B., and MacLusky, N. J., 1983, The relationship of circulating estradiol to tardive dyskinesia in men and post menopausal women, Psychoneuroendocrinology 8: 429–434.PubMedGoogle Scholar
  45. Godwin-Austen, R. B., and Clark, T., 1971, Persistent phenothiazine dyskinesia treated with tetrabenazine, Br. Med. J. 4: 25–26.PubMedGoogle Scholar
  46. Goldman, D., 1976, Treatment of phenothiazine-induced dyskinesia, Psychopharmacology 47: 271–272.PubMedGoogle Scholar
  47. Hall, C. D., Weiss, E. A., Morris, C. E., and Prange, A. J., 1972, Rapid deterioration of patients with parkinsonism following tryptophan-pyridoxine administration, Neurology 22: 232.Google Scholar
  48. Itil, T. M., Unverdi, C., and Mehta, D., 1974, Chlorazepate dipotassium in tardive dyskinesia, Am. J. Psychiatry 131: 1291.PubMedGoogle Scholar
  49. Jus, A., Jus, K., Gaulter, J., Villenueve, A., Pires, P., Pineau, R., and Villeneuve, R., 1974, Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome, Int. J. Clin. Pharmacol. Biopharm. 9: 138–145.Google Scholar
  50. Jus, A., Villeneuve, A., Gautier, J., Jus, K., Villeneuve, C., Pires, P., and Villeneuve, R., 1978, Deanol, lithium and placebo in the treatment of tardive dyskinesia, Neuropsychobiology 4: 140–149.PubMedGoogle Scholar
  51. Klawans, H. L., Jr., 1973, The pharmacology of tardive dyskinesia, Am. J. Psychiatry 130: 83–86.Google Scholar
  52. Klawans, H. L., and Rubovits, R., 1974, Effect of cholinergic and anticholinergic agents on tardive dyskinesia, J. Neur. Neurosurg. Psychiatry 27: 941–947.Google Scholar
  53. Korsgaard, S., 1976, Baclofen (Lioresal) in the treatment of neuroleptic-induced tardive dyskinesia, Acta Psychiatry. Scand. 54: 17–24.Google Scholar
  54. Korsgaard, S., Casey, D. E., and Gerlach, J., 1982a, High-dose des-tyrosine-gamma-endorphin in tardive dyskinesia, Psychopharmacology 78: 285–286.PubMedGoogle Scholar
  55. Korsgaard, S., Casey, D. E., and Gerlach, J., Hetmar, O., Kaldan, B., and Mikkelsen, L. B., 1982b, The effect of Tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia, Arch. Gen. Psychiatry 39: 1017–1021.Google Scholar
  56. Kruse, W., 1960, Persistent muscular restlessness after phenothiazine treatment: Report of 3 cases, Am. J. Psychiatry 115: 152–153.Google Scholar
  57. Kuhar, M. F., Pert, C. B., and Snyder, S. H., 1973, Regional distribution of opiate receptor binding in monkey and human brain, Nature 245: 447–450.PubMedGoogle Scholar
  58. Kunin, R. A., 1976, Manganese in dyskinesias, Am. J. Psychiatry 133: 105.Google Scholar
  59. Kurata, K., Hosokawa, K., and Koshino, Y., 1977, Treatment of neuroleptic-induced tardive dyskinesia with cyproheptadine, J. Neurol. 215: 295–298.PubMedGoogle Scholar
  60. Labrie, F., Beaulieu, M., Carom, M., and Raymond, V., 1978, The adenohypophyseal dopamine receptors, specificity and modulation of its activity by estradiol, in: Proceedings of the International Symposium on Prolactin ( A. Robyn and C. Harter, eds.), pp. 121–136, Elsevier/ North-Holland Biomedical Press, Amsterdam.Google Scholar
  61. Lahti, R. A., and Losey, E. G., 1974, Antagonism of the effects of chlorpromazine and morphine on dopamine metabolism by GABA, Res. Commun. Chem. Pathol. Pharmacol. 7: 31–40.PubMedGoogle Scholar
  62. Lautin, A., Stanley, M., Angrist, B., and Gershon, S., 1979, Extrapyramidal syndrome with sodium valproate, Br. Med. J. 2: 1035–1036.PubMedGoogle Scholar
  63. Linnoila, M., and Viukari, M., 1979, Sodium valproate and tardive dyskinesia, Br. J. Psychiatry 134: 223–224.PubMedGoogle Scholar
  64. Linnoila, M., Viukari, M., and Hietala, O., 1976, Effect of sodium valproate on tardive dyskinesia, Br. J. Psychiatry 129: 114–119.PubMedGoogle Scholar
  65. Lipsius, L. H., 1977, Barbiturates and tardive dyskinesia, Am. J. Psychiatry 134: 1162–1163.PubMedGoogle Scholar
  66. Lloyd, K. G., and Worms, P., 1981, Neuropharmacological actions of GABA agonists: Predictability for their clinical usefulness, in: Amino Acid Neurotransmitters ( F. V. DeFeudis and P. Mendel, eds.), pp. 59–67, Raven Press, New York.Google Scholar
  67. Mackay, A. V., Sheppard, G. P., Saha, B. K., Motley, B., Johnson, A. L., and Marsden, C. D., 1980, Failure of lithium treatment in established tardive dyskinesia, Psychol. Med. 10: 583–587.PubMedGoogle Scholar
  68. Massotti, M., Guidotti, A., and Costa, E., 1981, Characterization of benzodiazepine and gammaaminobutyric recognition sites and their endogenous modulators, J. Neuroscience 1: 409–418.Google Scholar
  69. McGeer, P. L., and McGeer, E. G., 1976, Enzymes associated with the metabolism of catecholamines, acetylcholine, and GABA in human controls and patients with Parkinson’s disease and Huntington’s chorea, J. Neurochem. 26: 65–76.PubMedGoogle Scholar
  70. Mehta, D., Mehta, S., and Mathew, P., 1976, Failure of deanol in treating tardive dyskinesia, Am. J. Psychiatry 133: 1467.PubMedGoogle Scholar
  71. Nagao, T., Ohshimo, T., Mitsunobu, K., Sato, M., and Otsuki, S., 1979, Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor, Biol. Psychiatry 14: 509–523.PubMedGoogle Scholar
  72. Nair, N. P. V., Yassa, R., Ruiz-Navarro, J., and Schwartz, G., 1978, Baclofen in the treatment of tardive dyskinesia, Am. J. Psychiatry 135: 1562–1563.PubMedGoogle Scholar
  73. Nair, N. P. V., Lal, S., Schwartz, G., and Thavundayil, J. K., 1980, Effect of sodium valproate and baclofen in tardive dyskinesia: Clinical and neuroendocrine studies, Adv. Biochem. Psychopharmacol. 24: 437–441.PubMedGoogle Scholar
  74. Nasrallah, H. A., Smith, R. E., Dunner, F. J., and McCalley-Whitters, M., 1982, Serotonin precursor effects in tardive dyskinesia, Psychopharmacology 77: 234–235.PubMedGoogle Scholar
  75. Nicoletti, F., Patti, F., Marano, P., Condorelli, D. F., Scarzella, L., Bergamasco, B., Marino, B., Reggio, A., and Scapagnini, U., 1983, Effects of salmon calcitonin administration on spontaneous or neuroleptically-induced dyskinesias, Acta Neurol. (Napoli) 5: 380–384.Google Scholar
  76. Norris, J. P., and Sams, R. E., 1977, More on the use of manganese in dyskinesia, Am. J. Psychiatry 134: 1448.PubMedGoogle Scholar
  77. O’Flanagan, P. M., 1975, Clonazepam in the treatment of drug-induced dyskinesia, Br. Med. J. 1: 269–270.PubMedGoogle Scholar
  78. Palfreyman, M. G., Huot, S., Lippert, B., and Schechter, P. J., 1978, The effect of gamma-acetylenic GABA, an enzyme-activated irreversible inhibitor of GABA-transaminase, on dopamine pathways of the extrapyramidal and limbic system, Eur. J. Pharmacol. 50: 325–336.PubMedGoogle Scholar
  79. Pedigo, N. W., Schallert, T., and Overstreet, D. M., 1979, Inhibition of in vivo 3H-spiperone binding by the proposed antipsychotic des-tyr-gamma-endorphin, Eur. J. Pharmacol. 60: 359–364.PubMedGoogle Scholar
  80. Perry, T., and Hansen, S., 1978, Biochemical effects in man and rat of three drugs which can increase brain GABA content, J. Neurochem. 30: 679–684.PubMedGoogle Scholar
  81. Pert, A., Rosenblatt, J. E., Sivit, C., Pert, C. B., and Bunney, W. E., 1978, Long term treatment with lithium prevents the development dopamine receptor supersensitivity, Science 201: 171–173.PubMedGoogle Scholar
  82. Pickar, D., and Davies, R. K., 1978, Tardive dyskinesia in younger patients, Am. J. Psychiatry 135: 385–386.PubMedGoogle Scholar
  83. Prange, A. J., Wilson, I. C., Morris, C. E., and Hall, C. D., 1973, Preliminary experience with tryptophan and lithium in the treatment of tardive dyskinesia, Psychopharmacol. Bull. 9: 3637.Google Scholar
  84. Price, T. R. P., and Levin, R., 1978, The effects of electroconvulsive therapy on tardive dyskinesia, Am. J. Psychiatry 135: 991–993.PubMedGoogle Scholar
  85. Raymond, V., Beaulieu, M., Labrie, R., and Boissier, J. R., 1978, Potent antidopaminergic activity of estradiol at the pituitary level of prolactin release, Science 200: 1173–1175.PubMedGoogle Scholar
  86. Reda, F. A., Scanlan, J. M., Kemp, K., and Escobar, J. L., 1974, Treatment of tardive dyskinesia with lithium carbonate, N. Engl. J. Med. 291: 850.PubMedGoogle Scholar
  87. Reda, F. A., Escobar, J. I., and Scanlan, J. M., 1975, Lithium carbonate in the treatment of tardive dyskinesia, Am. J. Psychiatry 132: 560–562.PubMedGoogle Scholar
  88. Recker, D., Anderson, B., Yackulic, C., Cooper, T. B., Banay-Schwartz, M., Leon, C., and Dolavka, J., 1982, Naloxone, tardive dyskinesia and endogenous beta-endorphin, Psychiatry Res. 7: 321–324.Google Scholar
  89. Rosenbaum, A. H., and de la Fuente, J. R., 1979, Benzodiazepines and tardive dyskinesia, Lancet 2: 900.PubMedGoogle Scholar
  90. Rosenbaum, A. H., Maruta, T., Duane, D. D., Auger, R. G., Martin, D. K., and Brenengen, E. E., 1980, Tardive dyskinesia in depressed patients: Successful therapy with antidepressants and lithium, Psychosomatics 20: 715–719.Google Scholar
  91. Saito, K., Konishi, S., and Otsuka, M., 1975, Antagonism between Lioresal and substance P in rat spinal cord, Brain Res. 97: 177–180.PubMedGoogle Scholar
  92. Scatton, B., Zivkovic, B., Dedek, J., Lloyd, K. G., Constantinidis, J., Tissot, R., and Bartholini, G., 1982, y-Aminobutyric acid (GABA) receptor stimulation III: Effect of progabide (SL 76002) on norepinephrine, dopamine, and 5-hydroxytryptamine turnover in rat brain areas, J. Pharmacol. Exp. Ther. 220: 678–688.Google Scholar
  93. Scatton, B., Zivkovic, B., and Nartholini, G., 1980, Differential influence of GABAergic agents on dopamine metabolism in extrapyramidal and limbic systems of the rat, Brain Res. Bull. 5 (Suppl. 2): 421–425.Google Scholar
  94. Schildkraut, J. J., Schanberg, S. M., and Kopin, I. J., 1966, The effects of lithium ion on 3Hnorepinephrine metabolism in brain, Life Sci. 5: 1479–1481.PubMedGoogle Scholar
  95. Schmidt, R. F., Vogel, M. E., and Zimmerman, M., 1967, Die Wirkung von Diazepam auf die prasynaptische Hemmung und andere Ruckenmarkreflexe, Arch. Pharmak. Exp. Path. 258: 6982.Google Scholar
  96. Schoemaker, H., and Nickolson, V. J., 1980, Effects of des-tyr’-gamma-endorphin on dopamine release from various rat brain regions in vitro, Life Sci. 27: 1371–1376.PubMedGoogle Scholar
  97. Sedman, G., 1976, Clonazepam in the treatment of tardive oral dyskinesia, Br. Med. J. 2: 583.PubMedGoogle Scholar
  98. Sevestre, P., Rondot, P., Bathien, N., Morselli, R. L., and VanLandeghem, V. H., 1982, The effect of progabide, a specific GABAergic agonist on neuroleptic-induced tardive dyskinesiaResults of a pilot study, 13th Collegium Internationale Neuro-Pharmacologicum C. I. N. P., abstracts. Vol. II, Jerusalem.Google Scholar
  99. Simpson, G. M., Branchey, M. H., Lee, J. H., Voitashevsky, A., and Zoubok, B., 1976, Lithium in tardive dyskinesia, Pharmakopsychiat. Neuropsychopharmakol. 9: 76–80.Google Scholar
  100. Simpson, G. M., Lee, J. H., Shrivastava, R. K., and Branchey, M. H., 1978, Baclofen in the treatment of tardive dyskinesia and schizophrenia, Psychopharmacol. Bull. 14: 16–18.Google Scholar
  101. Singh, M. M., 1976, Diazepam in the treatment of tardive dyskinesia, Int. J. Pharmacopsychiatry 11: 232–234.Google Scholar
  102. Singh, M. M., Nasrallah, H. A., Lal, H., et al.,1980, Treatment of tardive dyskinesia with diazepam: Indirect evidence for the involvement of limbic, possibly GABA-ergic mechanisms, Brain Res. Bull. 5:673–680.Google Scholar
  103. Singh, M. M., Becker, R. E., Pitman, R. K., Nasrallah, H. A., Lal, H., Dufresne, R. L., Weber, S. S., McCalley-Whitters, M., 1982, Drug-induced changes in tardive dyskinesia: Suggestions for a new conceptual model, Biol. Psychiatry 17: 729–742.PubMedGoogle Scholar
  104. Sovner, R., and Loadman, A., 1978, More on barbiturates and tardive dyskinesia, Am. J. Psychiatry 13: 382.Google Scholar
  105. Stewart, R. M., Rollins, J., Beckham, B., and Roffman, M., 1982, Baclofen in tardive dyskinesia patients maintained on neuroleptics, Clin. Neuropharmacol. 5: 365–373.PubMedGoogle Scholar
  106. Tamminga, C. A., Crayton, J. W., and Chase, T. N., 1979, Improvement in tardive dyskinesia after muscimol therapy, Arch. Gen. Psychiatry 36: 595–598.PubMedGoogle Scholar
  107. Tamminga, C. A., Tighe, P. J., Chase, T. N., DeFraites, G., and Schaffer, M. H., 1981, Destyrosine-gamma-endorphin administration in chronic schizophrenics, Arch. Gen. Psychiatry 38: 167–168.PubMedGoogle Scholar
  108. Tamminga, C. A., Thaker, G. K., Ferraro, T. N., and Hare, T. A., 1983, GABA agonist treatment improved tardive dyskinesia, Lancet 2: 97–98.PubMedGoogle Scholar
  109. Tell, G. P., Schechter, P. J., Koch-Weser, J., Cantiniaux, P., Chabannes, J. P., and Lambert, P. A., 1981, Effects of gamma-vinyl GABA, N. Engl. J. Med. 305: 581–582.PubMedGoogle Scholar
  110. Thaker, G. K., Hare, T. A., and Tamminga, C. A., 1983, GABA system: Clinical research and treatment of tardive dyskinesia, Mod. Probl. Pharmacopsychiatry, 21: 155–167.PubMedGoogle Scholar
  111. Thaker, G. K., Tamminga, C. A., Lafferman, J., Alphs, L. A., and Hare, T. A., GABA-mediated neural systems in tardive dyskinesia: Pathophysiology and treatment (submitted for publication).Google Scholar
  112. Uhrband, L., and Faurbye, A., 1960, Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy, Psychopharmacologia 1: 408–418.Google Scholar
  113. Verhoeven, W., van Praag, H. M., and Botter, P. A., 1978, (Des-tyr’)-gamma-endorphin in schizophrenia, Lancet 1: 1046.Google Scholar
  114. Verhoeven, W. M. A., van Praag, H. M., and van Ree, J. M., 1979, Improvement of schizophrenia patients treated with des-tyr’-gamma-endorphin (DyTE), Arch. Gen. Psychiatry 36: 294–298.PubMedGoogle Scholar
  115. Villeneuve, A., Langlier, P., and Bedard, P., 1978, Estrogens, dopamine and dyskinesias, Can. Psychiatr. Assoc. J. 23: 68–70.PubMedGoogle Scholar
  116. Villeneuve, A., Cazejust, T., and Côte, M., 1980, Estrogens in tardive dyskinesia in male psychiatric patients, Neuropsychobiology 6: 145–151.PubMedGoogle Scholar
  117. Volavka, J., Anderson, B., and Koz, G., 1982, Naloxone and naltrexone in mental illness and tardive dyskinesia, Ann. NYAcad. Sci. 398: 97–102.Google Scholar
  118. Walaas, I., and Fonnum, F., 1978, The distribution of putative momoamine, GABA, acetylcholine and glutamate fibers in the mesolimbic system, in: GABA-Neurotransmitters ( P. KorsgaardLarsen, J. Scheel-Kruger, and H. Kofod, eds.), pp. 60–73, Academic Press, New York.Google Scholar
  119. Walters, J. R., and Chase, T. N., 1977, GABA systems and extrapyramidal function, in: Neurotransmitter Function: Basic and Clinical Aspects (W. S. Fields, ed.), pp. 193–211, Atratton Intercontinental Medical Book Corporation, New York.Google Scholar
  120. Weber, S. S., Dufresne, R. L., Becker, R. E., and Mastrati, P., 1983, Diazepam in tardive dyskinesia, Drug Intel!. Clin. Pharm. 17: 523–527.Google Scholar
  121. Wolf, M. E., Keener, S., Mathis, P., and Mosnaim, A. D., 1983, Phenylethylamine-like properties of baclofen, Neuropsychobiology 9: 219–222.PubMedGoogle Scholar
  122. Yahr, M. D., Duvoisin, R. C., and Cote, L. D., 1969, Reversal of L-dopa effects in parkinsonism, Trans. Am. Neurol. Assoc. 94: 81–84.PubMedGoogle Scholar
  123. Yassa, R., Archer, J., and Cordozo, S., 1984, The long-term effect of lithium carbonate on tardive dyskinesia, Can. J. Psychiatry 29: 36–37.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • Larry D. Alphs
    • 1
  • John M. Davis
    • 2
  1. 1.Maryland Psychiatric Research Center, Department of PsychiatryUniversity of MarylandBaltimoreUSA
  2. 2.Illinois State Psychiatric InstituteChicagoUSA

Personalised recommendations